CBIO
Crescent Biopharma
CBIO
CBIO
80 hedge funds and large institutions have $535M invested in Crescent Biopharma in 2017 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
0.02% more ownership
Funds ownership: 0.91% → 0.93% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
46% less call options, than puts
Call options by funds: $2.14M | Put options by funds: $3.96M
Holders
80
Holding in Top 10
2
Calls
$2.14M
Puts
$3.96M
Top Buyers
| 1 | +$22.8M | |
| 2 | +$12M | |
| 3 | +$11.4M | |
| 4 |
Axa
Paris,
France
|
+$8.58M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$8.23M |
Top Sellers
| 1 | -$45.9M | |
| 2 | -$11.2M | |
| 3 | -$4.72M | |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.29M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.1M |